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Abstract.
Background: Neuropsychiatric symptoms (NPS) are non-cognitive, behavioral, or psychiatric symptoms, common in mild
cognitive impairment (MCI) and associated with a higher risk of dementia. Mild behavioral impairment (MBI) is a validated
diagnostic entity, that describes the emergence of later life NPS in pre-dementia states. The Mild Behavioral Impairment
Checklist (MBI-C) is the first measure developed to assess MBI.
Objective: To estimate the prevalence of MBI in people with MCI and to study the score distribution, sensitivity, specificity,
diagnostic utility of the MBI-C, and its correlations with neuropsychological tests.
Methods: One hundred eleven MCI participants were evaluated with the Questionnaire for Subjective Memory Complaints
(QSMC), Mini-Mental State Examination, Cambridge Cognitive Assessment-Revised, Neuropsychiatric Inventory-
Questionnaire (NPI-Q), Geriatric Depression Scale-15 items (GDS-15), Lawton and Brody Index, and the MBI-C, which was
administered by phone to participants’ informants. Descriptive, logistic regression, ROC curve, and bivariate correlations
analyses were performed.
Results: MBI diagnosis prevalence was 14.2%. The total MBI-C score differentiated people with MBI at a cutoff-point of
6.5, optimizing sensitivity and specificity. MBI-C total score correlated positively with NPI-Q, QSMC, GDS-15, and Lawton
and Brody Index.
Conclusion: The total MBI-C score, obtained by phone administration, is sensitive for detecting MBI in people with MCI.
The MBI-C scores indicated that MCI participants had subtle NPS that were correlated to their subjective memory complaints
reported by informants, depressive symptoms, and negatively with Instrumental Activities of Daily Living. Further research
should be done to clarify the predictive role of NPS in MCI for incident dementia.
Keywords: Behavioral and psychological symptoms of dementia, dementia, mild behavioral impairment, mild cognitive
impairment, neuropsychiatric symptoms, preclinical dementia, prodromal dementia
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INTRODUCTION
Neuropsychiatric symptoms in mild cognitive
impairment
Neuropsychiatric symptoms (NPS), also known as
behavioral and psychological symptoms of dementia
(BPSD), are non-cognitive, behavioral, or psychi-
atric symptoms that include disturbances of mood,
perception, and behavior related to a neurocognitive
disorder [1].
NPS are associated with greater functional impair-
ment [2], accelerated progression to dementia [3],
higher burden of neuropathologic markers of demen-
tia [4], greater caregiver stress [5], and poorer quality
of life [6]. NPS are common in mild cognitive impair-
ment (MCI), with prevalence from 35% to 85% [7, 8].
People with MCI and NPS have a greater impairment
in global, cognitive, and functional scores compared
to those who have MCI without NPS [9]. NPS also
increase the likelihood of developing dementia in
people with MCI at baseline [3, 10] and thus are
important targets for further research in dementia
prevention and prognostication.
Mild behavioral impairment diagnosis
To facilitate this further research into NPS and
risk of dementia, and make explicit the relationship
between NPS and MCI, the NPS Professional Inter-
est Area of the International Society to Advance
Alzheimer’s Research and Treatment (ISTAART),
a subgroup of the Alzheimer’s Association (AA),
published research diagnostic criteria for Mild
Behavioral Impairment (MBI) [11] (Table 1). The
ISTAART-AA MBI criteria mandate that NPS be
emergent in later life with a minimum six-month
duration, to minimize the inclusion of transient and
reactive states, and to increase signal detection. Addi-
tionally, formal psychiatric illness is an exclusion
criterion, and precludes an MBI diagnosis. In this
framework then, MBI reflects the neurobehavioral
axis of possible predementia risk states, and MCI
reflects the neurocognitive axis. Accordingly, symp-
toms on these axes can emerge together (MCI and
MBI), independently (MCI or MBI), or sequen-
tially (MBI before MCI or vice versa) in advance
of dementia. MBI is a validated c nstruct. In a 5-
year longitudinal study of older adults, MBI had
a higher conversion rate to dementia than a psy-
chiatric comparator group consisting of late life
psychiatric disorders [12], highlighting the distinc-
tion between MBI and late life psychiatric disorders,
and the prognostic utility of identifying MBI sepa-
rately. Thus, detecting the NPS that constitute MBI
may aid in earlier detection of dementia at the pro-
dromal phase, in advance of cognitive impairment.
ISTAART further operationalized the measurement
of MBI with the development of the Mild Behav-
ioral Impairment-Checklist (MBI-C, available at
http://www.MBItest.org) [13], a rating scale designed
to elicit emergent NPS in a community dwelling,
functionally independent, older population, in accor-
dance with the ISTAART-AA MBI criteria. The
explicit goal of the MBI-C is MBI case ascertainment,
but further validation of its performance is required.
Table 1
ISTAART-AA MBI criteria [11]
1) Changes in behavior or personality observed by patient, informant, or clinician, starting later in life (age ≥50 years) and persisting at
least intermittently for ≥6 months. These represent a clear change from the person’s usual behavior or personality as evidenced by at





e) abnormal thought and perception;
2) Behaviors are of sufficient severity to produce at least minimal impairment in at least one of the following areas:
a) Interpersonal relationships
b) Other aspects of social functioning
c) Ability to perform in the workplace.
The patient should generally maintain his/her independence of function in daily life, with minimal aids or assistance.
3) Although comorbid conditions may be present, the behavioral or personality changes are not attributable to another current psychiatric
disorder, traumatic or general medical causes, or the physiological effects of a substance or medication
4) The patient does not meet criteria for a dementia syndrome. (e.g., Alzheimer’s disease, frontotemporal dementia, dementia with Lewy
bodies, vascular dementia, other dementia). MCI can be concurrently diagnosed with MBI.
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Objectives
To estimate: 1) the prevalence of MBI diagnosis
and score distribution in a primary care popula-
tion with MCI; 2) the sensitivity and specificity of
the telephone-administered MBI-C and its utility for
diagnosing MBI; and 3) the relationships between
NPS, cognitive status, and functional performance in
instrumental activities of daily living.
METHODS
Participants
One hundred eleven participants aged ≥50 years
with MCI were recruited from patients belonging to
all socioeconomic levels attending Public Primary
Care Health Centers in Santiago de Compostela (the
capital of the autonomous region of Galicia, North-
West of Spain) with subjective cognitive complaints
(SCC). Participants were excluded if they had: prior
diagnosis of depression or other psychiatric distur-
bances, according to the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5)
criteria [14]; prior diagnosis of neurological disease,
including probable Alzheimer’s disease (AD) or other
types of dementia, according to the National Insti-
tute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) [15] and
DMS-5 criteria [14]; previous brain damage or brain
surgery; previous chemotherapy; prior diagnosis of
diabetes type II; sensory or motor disturbances; and
consumption of substances that might affect normal
performance of the tasks.
The participants underwent clinical, neurologi-
cal, and neuropsychological examination conducted
respectively by general practitioners, cognitive
neurologists, and neuropsychologists specialized in
aging and dementia. All assessments included in this
study were completed in a period of three weeks
for each participant. The Charlson’s Comorbidity
Index [16] was obtained from the medical history.
MCI was diagnosed in accordance with Petersen’s
[17] criteria revised by Albert et al. [18]: 1) evi-
dence of concern corroborated by an informant about
a change in cognition, in comparison with the pre-
vious level; 2) evidence of poorer performance in
one or more cognitive domains that is greater than
expected for the patient’s age and educational back-
ground; 3) preservation of independence in functional
abilities; and 4) non-fulfilment of diagnostic criteria
for dementia (NINCDS-ADRDA [15] and DSM-5
criteria [14]).
Study protocol approvals, registrations, and
patient consents
The study was approved by the Ethics in Clini-
cal Research Committee of the Galician Government
and was carried out in accordance with the Declara-
tion of Helsinki, as revised in Fortaleza 2013. Written
informed consent was obtained from all participants
before the study, and patient anonymity and privacy
has been preserved.
Sociodemographic, cognitive, and functional
evaluation
A questionnaire on sociodemographic data was
used to obtain information from the patients. A short
Spanish version of the Questionnaire for Subjective
Memory Complaints (QSMC) [19], comprised of 7
items each scored on a Likert scale from 1 to 5 (max-
imum 35), was administered to participants and to a
family member in order to assess SCC. The QSMC
items were: 1) “Do you forget where you left your
things?”; 2) “Do you forget names of people you just
met?”; 3) “Do you forget names of close relatives or
friends?”; 4) “Do you often have a word on the tip
of your tongue?”; 5) “Are you lost in familiar places
where you have been before?”; 6) “Are you lost in
unfamiliar places where you have been a few times?”;
and 7) “Do you forget things you planned to do?”.
The general cognitive functioning of participants
was evaluated by the Spanish version [20] of the Mini-
Mental State Examination (MMSE) [21]. Cognitive
impairments in several domains were evaluated by
the Spanish version [22] of the Cambridge Cognitive
Assessment-Revised [22] (CAMCOG-R) [23] and
other tests. We assessed: 1) attention with the Trail
Making Test (A) [24] and the Attention and Calcula-
tion CAMCOG-R subscale; 2) executive functioning
with Trail Making Test (B) [24], Phonological ver-
bal fluency [25] (say in one min words starting with
“p”), and the Executive Function CAMCOG-R sub-
scale; 3) memory with by the Spanish version [26]
of the California Verbal Learning Test (CVLT) [27]
(which measures List A Total Recall, and Long-Delay
Free Recall) and the Memory CAMCOG-R subscale;
and 4) language with the Spanish version of the
Boston naming test (BNT) [28], Semantic verbal flu-
ency (animals) [25], and the Language CAMCOG-R
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considered when patients scored 1.5 SDs below age
and education norms in at least two of the cognitive
measures of that domain [29]. According to these cri-
teria, 64 patients were diagnosed as multiple domain
amnestic MCI, 11 as multiple-domain non-amnestic,
5 as single-domain non-amnestic, and 26 as single-
amnestic (five participants were excluded because
MBI diagnosis could not be confirmed from all data
sources). Functional assessment was done using the
Spanish version of the Lawton and Brody Index (max-
imum possible scoring = 8) to evaluate Instrumental
Activities of Daily Living (IADL) [30].
Measurement of neuropsychiatric symptoms
To assess NPS we used: the 15-item Spanish ver-
sion [31] of the Geriatric Depression Scale (GDS-15)
[32], the Spanish version [33] of the Neuropsychiatric
Inventory Questionnaire (NPI-Q) [34], a brief form
of the NPI [35], and the Spanish version [36] of the
MBI-C [13].
The MBI-C [13] includes 34 items organized in
five domains: 1) decreased motivation (six items
including assessments of cognitive, behavioral, and
emotional apathy); 2) affective dysregulation (six
questions including low mood, anhedonia, hopeless-
ness, and guilt, and one question each for worry
and panic); 3) impulse dyscontrol (12 questions
describing agitation, aggression, impulsivity, reck-
lessness, and abnormal reward and reinforcement);
4) social inappropriateness (five questions assess-
ing sensitivity, empathy, and tact); 5) abnormal
thought and perception (five questions assessing sus-
piciousness, grandiosity, and auditory and visual
hallucinations). For each item, a “yes” or “no” ques-
tion is followed by a severity rating scale of 1- mild,
2-moderate, or 3-severe. Symptoms should represent
a meaningful change from baseline behaviors. A neu-
ropsychologist administered the Spanish version of
the questionnaire [37] by phone interview to a rela-
tive of the patient, to minimize travel to the health
center and optimize retention. The mean time taken
for the application was around 10–15 min.
Diagnosis of MBI was made via a series of semi-
structured independent interviews with patients and
relatives, conducted by specialized neuropsycholo-
gists, in addition to medical records, in accordance
with the ISTAART-AA diagnostic criteria (Table 1).
To determine criterion one, we asked for the pres-
ence of the symptoms described in the criteria over
the last six months in the initial phone interview, and
then confirmed them using the NPI-Q (administered
to informant on the patient’s assessment session).
For the NPI-Q, both 1 month (proper measure of
the instrument) and six-month symptom duration
were queried (as required in the criteria). For crite-
ria two and three (Table 1), information was obtained
from the phone interview. Criterion four (Table 1)
was obtained from the final assessment and diag-
nosis. Definite MBI diagnosis was made by the
research team after incorporating several sources of
information that included extensive clinical assess-
ments, cognitive and neuropsychiatric testing, and
this served as the reference standard for MBI-C
performance validation.
Statistical analyses
Data were analyzed using SPSS v.20. Total scores
were calculated for each questionnaire as well as
domain scores for the MBI-C using descriptive anal-
ysis. Exploratory analyses were performed to detect
any errors in the data. The prevalence of MBI diag-
nosis and the distribution of the MBI-C total score
and domains scores in the whole sample, patients
with MBI and patients without MBI were determined
using frequency and descriptive analyses. Charac-
teristics of the sample and comparisons between
groups of patients with and without MBI were
also performed using descriptive analysis and Inde-
pendent Samples T-Tests. Furthermore, to compare
one-month NPI-Q and six months NPI-Q versions in
each group (with and without MBI) and in all the
sample, we performed Paired Samples T-Tests. The
relationships between the total score on the MBI-
C and sociodemographic (age, years of education,
Charlson’s Comordirdity Index, and QSMC), cog-
nitive measures (CAMCOG-R and MMSE), NPS
scores (one-month NPI-Q, six-months NPI-Q, and
GDS-15), and functional results (IADL) were exam-
ined using Spearman bivariate correlations because
several measures did not follow a normal distribu-
tion. Binary logistic regression was used to determine
the predictive value of the MBI-C, with MBI diagno-
sis the outcome variable and the MBI-C total score
the predictor variable. To determine the utility of the
MBI-C total score for diagnosing MBI and the sen-
sitivity and specificity of the cut-off point, a ROC
curve analysis was performed, with the total score on
the MBI-C the contrast variable and the MBI diag-
nosis the state variable. The ROC curve analysis was
made on a non-parametric assumption since the dis-
tribution of the scores was not normal. The level of
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Table 2
Descriptive parameters of the sample
All (n = 106) With MBI (n = 15) Without MBI (n = 91) Comparisons
between groups
Variables Mean (SD) Range Mean (SD) Range Mean (SD) Range t (106)
Age 70.04 (8.33) 50–84 71.67(6.78) 60–81 69.47 (8.6) 50–84 0.94
Years of Education 7.89 (4.07) 1–25 8.73 (4.43) 3–17 7.70 (4.03) 1–25 0.90
Charlson’s Comorbidity Index 0.44 (0.67) 0–3 0.53 (0.74) 0–2 0.43 (0.67) 0–3 0.50
QSMC (patient) 16.00 (3.97) 8–29 16.33 (4.15) 8–22 16.10 (3.92) 8–29 0.21
QSMC (informant) 16.59 (4.33) 7–26 18.8 (4.16) 9–26 16.25 (4.2) 7–26 2.11∗
IADL 7.20 (1.25) 5–8 6.60 (1.60) 5–8 7.29 (1.18) 5–8 –2.02
GDS-15 3.16 (2.50) 0–11 4.80 (2.42) 1–9 2.8 (2.3) 0–11 2.86∗∗
NPI-Q 1 month 3.73 (3.25) 0–12 6.80 (2.37) 3–12 3.12 (3.09) 0–12 4.38∗∗
NPI-Q 6 months 2.82 (3.03) 0–12 6.60 (2.13) 3–11 2.10 (2.69) 0–12 6.14∗∗
MBI-C 5.08 (5.45) 0–23 13.93 (5.63) 7–23 3.55 (3.70) 0–12 9.22∗∗
MBI, mild behavioral impairment; SD, standard deviation; QSMC, Questionnaire for Subjective Memory Complaints; IADL, Instrumental
Activities of Daily Living; GDS-15, Geriatric Depression Scale-15 items; NPI-Q, Neuropsychiatric Inventory-Questionnaire; MBI-C, Mild
Behavioral Impairment-Checklist. ∗significant at p < 0.05, ∗∗the significant at p < 0.01.
RESULTS
Descriptive parameters of the sample
Of the 111 participants, five were excluded
because, although they were evaluated with the MBI-
C, the MBI diagnosis could not be confirmed from
all data sources required for the reference stan-
dard. Sixty-eight participants were women (64.2%
of the sample). Descriptive parameters of the total
sample and patients with and without MBI in the
variables age, years of education, QSMC from
the patient, Charlson’s Comorbidity Index, QSMC
from the informant, GDS-15, one-month and six-
months NPI-Q and IADL are shown in Table 2.
Descriptive parameters of cognitive measures are
displayed in Table 3. Comparison between patients
with and without MBI diagnosis (Independent Sam-
ples T-Tests) showed no significant differences in
age, years of education, Charlson’s Comorbidity
Index, QSMC from the patient and Lawton and
Brody Index. Significant differences were found
only in QSMC from the relative, GDS-15, one-
month and six-moths NPI-Q and MBI-C, with higher
scores for patients with MBI (Table 2). Com-
parisons between patients with and without MBI
diagnosis (Independent Samples T-Tests) showed
no significant differences in cognitive measures
(Table 3).
In each group (with and without MBI) and in the
whole sample, we performed two Paired Samples T-
Tests to compare the scores in the one-month NPI-Q
and the six-month NPI-Q. In participants with MBI,
there was no differences between one-month NPI-Q
and six-months NPI-Q versions (t = 1.38; d.f. = 14;
p = 0.19), whereas in participants without MBI, we
found significant differences between one-month
NPI-Q and six-months NPI-Q (t = 5.06, d.f. = 90;
p > 0.0001), with higher scores in the one-month
version. In the whole sample, we found signif-
icant differences between one-month NPI-Q and
six-month NPI-Q (t = 5.26; d.f. = 105; p < 0.0001),
with higher scores in the one-month version.
Descriptive parameters of the scoring in each
of the five domains and total MBI-C for patients
with and without MBI, as well as for all the
sample, are shown in Table 4. Results from
Independents Samples T-Tests showed significant
differences between participants with and without
MBI in four domains: decreased motivation, affec-
tive dysregulation, impulse dyscontrol, and social
inappropriateness, with higher scores for participants
with MBI. No significant differences were found in
abnormal thought and perception (Table 4).
In the whole sample, percentile 25 was 0.0 for all
domains, and 0.7 for total scoring; percentile 50 was
between 0 and 1, and 3.5 for total scoring; percentile
75 and 90 were between 0 and 6 for all domains and 12
for total scoring (maximum possible for total scoring,
102) (Table 5). The total MBI-C scoring was low,
25 participants (23.6%) scored 0 and 12 participants
(11.3%) scored 1 (Fig. 1). The prevalence of MBI
according to ISTAART-AA diagnostic criteria was
14.2%.
For patients with MBI, percentile 25 ranged from 0
to 2 for all domains, and 9 for total scoring; percentile
50 was between 0.0 and 5, and 12 for total scoring;
percentile 75 were between 0 and 8 for all domains
and 19 for total scoring; percentile 90 was between
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Table 3
Cognitive measures of the sample
Cognitive measures All (n = 106) With MBI (n = 15) Without MBI (n = 91) Comparisons
between groups
Mean (SD) Range Mean (SD) Range Mean (SD) Range t (106)
General functioning
MMSE 26.39 (2.47) 18–30 25.4 (3.68) 18–29 26.55 (2.45) 21–30 –1.55
CAMCOG-R 82.20 (9.63) 55–102 83.07 (9.21) 68–99 82.05 (9.94) 55–102 0.37
Attention
TMT-A (s) 75.29 (40.71) 21–202 69.67 (37.82) 31–180 77.00 (41.70) 21–202 –0.64
Attention calculation
(CAMCOG-R)
6.75 (1.88) 2–9 6.8 (1.93) 3–9 6.74 (1.89) 2–9 0.01
Executive Function
TMT-B (s) 252.08 (166.27) NA-840 263.64 (123.35) NA-493 251.99 (175.22) NA-840 0.24
Phonological Verbal
fluency (words that start
with “p”)
9.87 (5.13) 1–26 9.33 (5.03) 2–21 10.01 (5.28) 11–26 –0.46
Executive Function
(CAMCOG-R)
15.83 (4.42) 6–27 16.13 (4.27) 10–25 15.86 (4.55) 6–27 0.21
Memory
CVLT List A total recall 38.06 (12.41) 5–63 36.26 (13.76) 19–62 38.11 (12.19) 5–62 –0.53
CVLT Long Delay Free
Recall
6.28 (3.93) 0–15 5.73 (5.43) 0–13 6.32 (3.69) 0–15 –0.53
Memory (CAMCOG-R) 18.23(3.69) 7–25 18.73 (3.05) 14–24 18.11 (3.86) 7–25 0.59
Language
BNT 41.30 (9.42) 13–59 43.33 (10.36) 22–59 40.97 (9.40) 13–58 0.88
Semantic verbal Fluency
(animals)
14.48 (4.44) 5–33 15.13 (4.45) 10–27 14.37 (4.50) 5–33 0.60
Language (CAMCOG-R) 24.77 (2.41) 19–30 24.93 (2.98) 19–30 24.78 (2.33) 19–29 0.22
MBI, mild behavioral impairment; SD, standard deviation; MMSE, Mini-Mental State Examination; CAMCOG-R, Cambridge Cognitive
Examination-Revised; TMT-A, Trail Making Test-A form; TMT-B, Trail Making Test-B form; CVL, California Verbal Learning Test; BNT,
Boston Naming Test; In TMT-B, the range is from NA, non-applicable, that means the subject was not able to complete the test, to a maximum
of 840 seconds. No significant differences were found between groups in any of the cognitive measures.
Table 4
Descriptive parameters of the scores in MBI-C domains for all the sample and for patients with MBI and without MBI
MBI-C domains All (n = 106) With MBI (n = 15) Without MBI (n = 91) Comparisons
between groups
Mean (SD) Range Mean (SD) Range Mean (SD) Range F (1, 105)
Decreased motivation 1.27 (2.06) 0–11 3.93 (3.19) 0–11 0.82 (1.38) 0–6 6.37∗∗
Affective dysregulation 1.70 (2.45) 0–11 4.60 (3.91) 0–11 1.19 (1.70) 0–7 5.67∗∗
Impulse dyscontrol 1.92 (2.50) 0–11 4.87 (3.18) 0–11 1.41 (1.98) 0–10 5.63∗∗
Social inappropriateness 0.15 (0.49) 0–3 0.46 (1.06) 0–3 0.09 (0.29) 0–1 2.79∗∗
Abnormal thought and perception 0.04 (0.19) 0–1 0.07 (0.26) 0–1 0.34 (0.18) 0–1 0.59
MBI, mild behavioral impairment; MBI-C, Mild Behavioral Impairment-Checklist; SD, standard deviation. ∗significant at p < 0.05, ∗∗the
significant at p < 0.01.
Table 5
Percentile distribution of the scores in the five domains of the MBI-C for all the sample and for patients with MBI and without MBI
MBI domains All (n = 106) With MBI (n = 15) Without MBI (n = 91)
%ile %ile %ile %ile %ile %ile %ile %ile %ile %ile %ile %ile
25 50 75 90 25 50 75 90 25 50 75 90
Interest, Motivation & Drive 0 0 2 4 2 3 6 9.8 0 0 1 3
Mood or Anxiety 0 1 2 5.7 1 4 8 10.4 0 0 2 4
Delay Gratification & Control 0 1 3 6 2 5 6 10.4 0 1 2 3.2
Societal Norms 0 0 0 1 0 0 0 3 0 0 0 0.2
Held Beliefs & Sensory Experiences 0 0 0 0 0 0 0 4 0 0 0 0
Total Scoring 0.7 3.5 9 12 9 12 19 23 0 2 5 10
MBI-C, Mild Behavioral Impairment-Checklist; MBI, mild behavioral impairment; %ile25, percentile 25; %ile50, percentile 50; %ile75,







S.C. Mallo et al. / Assessing MBI with the MBI-C in People with MCI 7
Fig. 1. Distribution of the total score in the MBI-C, determined using frequency analyses. MBI-C, Mild Behavioral Impairment-Checklist.
None of the participant obtained scores between 13–15 nor 20–22.
(Table 5). For patients without MBI, percentile 25
was 0 to 2 for all domains and total scoring; per-
centile 50 was between 0.0 and 1, and 2 for total
scoring; percentile 75 was between 0 and 2 for all
domains and 5 for total scoring; percentile 90 was
between 0 and 4 for all domains and 10 for total
scoring (Table 5).
Spearman correlations between measures
MBI-C total scoring correlated positively with
age (ρ = 0.26; p < 0.01), one-month NPI-Q (ρ = 0.62;
p < 0.01), six-months NPI-Q (ρ = 0.67; p < 0.01),
QSMC from the informant (ρ = 0.46; p < 0.01),
GDS-15 (ρ = 0.23; p < 0.05), and negatively with
IADL (ρ = –0.26; p < 0.05). No correlation was
found between the MBI-C and years of educa-
tion (ρ = –0.10; p = 0.29), Charlson’s Comorbid-
ity Index (ρ = 0.07; p = 0.45), QSMC from the
patient (ρ = –0.03 p = 0.77), CAMCOG-R (ρ = –0.08
p = 0.40), or MMSE (ρ = –0.14 p = 0.16) (Table 6).
MBI diagnosis
Taking into account that age was positively cor-
related with the MBI-C total score, we tested two
logistic regression models: the first one, with MBI-
C total score as predictor of MBI diagnosis and the
second one, adding age as covariate. The first logis-
tic regression model showed that MBI-C score was a
significant predictor of MBI diagnosis ( = –0.48; ST.
E = 0.13; Wald = 14.22; df = 1, p < 0.0001; OR = 0.62
CI (95%) = 0.48–0.79). Nagelkerke R2 showed that
the model explains 64% of the variance. The Hosmer-
Lemeshow test indicated a good fit for the regression
model (χ2 = 10.71, df = 8, p = 0.22). The second
model (with age as covariate) indicated that age was
not significant ( = –0.06; ST. E = 0.06; Wald = 1.14;
df = 1, p = 0.286; OR = 0.939 CI (95%) = 0.83 – 1.05),
the variance explained was 64% (Nagelkerke R2),
and the goodness of fit was the same as the first
one. Therefore, we decided to take the first model,
with only the MBI-C total score, as the best one.
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Table 6
Spearman correlations between MBI-C total scoring and scoring in NPI-Q, CAMCOG-R, MMSE, QSMC from the patient, QSMC from the
relative, GDS-15 and IADL
Neuropsychological Age Years of Charlson’s QSMC QSMC IADL GDS- One Six MMSE CAMCOG MBI-C
tests education Comorbidity (patient) (relative) 15 month months
Index NPI-Q NPI-Q
Age




QSMC (patient) –0.85 0.09 0.04
QSMC (relative) 0.29∗∗ –0.07 0.13 0.32∗∗
IADL –0.42∗∗ 0.13 –0.19 0.10 –0.14
GDS-15 0.06 –0.10 –0.06 0.21∗ 0.17 0.09
One-month NPI-Q 0.18 –0.10 –0.09 0.02 0.35∗∗ –0.24∗ 0.38∗∗
Six-months NPI-Q 0.11 –0.10 –0.03 0.00 0.27∗∗ –0.13 0.31∗∗ 0.81∗∗
MMSE –0.51∗∗ 0.34∗∗ –0.14 0.06 –0.24∗ 0.13 –0.03 –0.14 –0.14
CAMCOG –0.57∗∗ 0.58∗∗ –0.07 –0.02 –0.24∗ 0.17 –0.10 –0.09 –0.06 –0.65∗∗
MBI-C 0.26∗∗ –0.10 0.07 –0.03 0.46∗∗ –0.26∗ 0.23∗ 0.62∗∗ 0.67∗∗ –0.14 –0.08
MMSE, Mini-Mental State Examination; CAMCOG-R, Cambridge Cognitive Examination- Revised; QSMC, Questionnaire for Subjective
Memory Complaints; NPI-Q, Neuropsychiatric Inventory-Questionnaire; GDS-15, Geriatric Depression Scale-15 items; IADL, Activities
of Daily Living; MBI-C, Mild Behavioral Impairment-Checklist. ∗significant at p < 0.05, ∗∗the significant at p < 0.01.
differentiated people with and without MBI diagno-
sis, and the cutoff point 6.5 reached sensitivity = 1.00,
specificity = 0.78 and AUC = 0.93, p < 0.001 (Fig. 2).
DISCUSSION
To our knowledge, this is the first validation study
of the MBI-C in a sample of people with MCI. We
found that the prevalence of MBI in our primary care
MCI sample was 14.2%, and that a cut-point of 6.5
on the MBI-C best differentiated patients with MBI
from those without.
Previous studies, using traditional NPS rating
scales such as the NPI-Q, indicated that the NPS
prevalence in MCI populations ranges from 35% up
to 85% [7, 8]. Using a transformation algorithm of
the NPI score to capture criterion one of MBI, the
prevalence estimated in two recent studies was 85.3%
in a clinical sample [38] and 48.9% in a commu-
nity sample [39]. These percentages are significantly
higher than in our sample, possibly due to the short
frame of reference of 1 month of symptoms, required
by the NPI, compared to the more rigorous expec-
tation of six months of symptom duration and later
life onset of symptoms in the MBI-C. Thereby, the
MBI-C minimizes the inclusion of transient and reac-
tive states [11] which may cloud the diagnosis. Our
results comparing the scores of the two NPI-Q ver-
sions (one and six months) show that the 6-month
reference range is more rigorous. Additionally, our
diagnosis was made in a stricter way by incorporat-
ing all the four ISTAART-AA criteria. Importantly,
many patients from our study did not meet criterion
two, because NPS were not of sufficient severity to
produce at least minimal impairment in interpersonal
relationships, other aspects of social functioning or
ability to perform in the workplace. This requirement
speaks to the clinical relevance of the ISTAART-AA
MBI criteria, and may increase diagnostic specificity
by excluding symptoms with no functional impact.
The findings also suggest that the phone admin-
istration of the MBI-C is useful for detecting MBI
in people with MCI. The cutoff point of 6.5 signif-
icantly classified people with MBI diagnoses with
a sensitivity of 100% and a specificity of 78.20%.
Since the MBI-C was developed specifically as a
case ascertainment instrument for the ISTAART-AA
MBI criteria, and structured to be consistent with
the MBI domains, high sensitivity and specificity
was expected. The telephone administration could be
highly beneficial in populations that are dispersed,
where the residents have difficulties traveling to the
health care centers, or when the informants are not
able to go there due to health reasons or agenda. Even
for participants and clinic patients who live close to
research or clinical centers, collateral data gathered
via telephone MBI-C administration can generate
important information on the natural history and type
of NPS in participants, coloring and refining demen-
tia risk assessment. Moreover, in our study, a clinician
conducted the MBI-C by phone, but more investiga-
tions should be done with face-to-face assessments to
generate other validations and to test the equivalence
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Fig. 2. ROC curve, with the total score on the MBI-C as the contrast variable and the MBI diagnosis as the state variable. MBI-C, Mild
Behavioral Impairment-Checklist; MBI, mild behavioral impairment.
The MBI-C total score showed a mean signif-
icant positive correlation with one-month NPI-Q,
six-month NPI-Q, and with GDS-15, indicating the
validity of the MBI-C to assess NPS. In accordance
with these results, our analyses have also shown that
patients with MBI have significantly higher scores
on the NPI-Q, GDS-15, and in four of the five
domains of the MBI-C (decreased motivation, affec-
tive dysregulation, impulse dyscontrol, and social
inappropriateness), than patients without MBI. NPS
are common in the early clinical stages of neurocog-
nitive disorders, with prevalence estimates ranging
from 35–85%, due to differences in study setting,
demographics, MCI diagnosis, and instruments used
[7, 8]. Depression is one of the most common symp-
toms in MCI, with a recent meta-analysis estimating
prevalence at 32%, but being higher in clinical than in
community samples [40]. MBI-C correlation with the
GDS provides reassurance that depressive symptoms
are captured with the MBI-C.
The MBI-C detected subtle NPS that were corre-
lated with functional impairment as measured by the
Lawton and Brody IADL Index. This finding sug-
gests that the emergence of NPS may be related to an
early functional impairment. This result is in accor-
dance with criterion two of the MBI diagnosis [11],
which stipulates that NPS produce minimal impair-
ment in interpersonal relationships, other aspects of
social functioning, or ability to perform at the work-
place. Commonly, people with MCI have problems
performing complex functional tasks which they used
to perform in the past [18]. In MBI, these impairments
in social, occupational, or interpersonal function must
be related to changes in personality and behav-
ior, and not due to changes in cognition [11]. This
result highlights the importance of an early assess-
ment of functionality in people at risk of cognitive
impairment. While the expectation that functional
impairment is due to NPS, and that this increases
diagnostic specificity, the converse argument also
applies. It is possible that awaiting functional impair-
ment may result in diagnostic delays, missing the
mildest or earliest of symptoms, and chances for early
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Our results have also indicated that patients with
MBI have higher scores on QSMC from the infor-
mants than those without MBI. The significant
positive correlation between MBI-C and subjective
cognitive performance as measured by the QSMC
is relevant, taking into account that SCC are an
important criterion for the diagnosis of MCI [18].
These findings highlight the importance of testing
NPS in people with MCI because they may be early
markers of cognitive impairment and therefore early
indicators of dementia. No correlation was found
between the MBI-C and QSMC from the patient.
Juncos-Rabadán et al. [42] concluded that memory
difficulties reported by the informant, not the partic-
ipants themselves, have a greater prognostic value
predicting objective performance. Further studies are
needed to determine the relationship between SCC
and NPS, and which type of SCC (reported by the
patients themselves or by the informants) are more
accurate. No correlation was found between the MBI-
C and objective cognitive measures (CAMCOG-R
and MMSE). This supports the notion that while
MBI and MCI can co-occur, they reflect different
pre-dementia syndromes (neurobehavioral and neu-
rocognitive), and that MBI is not simply a function of
cognitive impairment [11]. Future investigations on
this interesting topic are recommended.
Our study is characterized by several strengths. A
detailed neurocognitive assessment, including tasks
with norms for age and education, was performed.
To assess cognitive deficits, not only the MMSE, a
screening test, but also the CAMCOG-R, an exten-
sive battery, was conducted. Hence, classification of
participants was made by diagnostic criteria, instead
of cutoff points in screening tasks. Further, we used
the MBI-C, an instrument specially designed to detect
NPS in pre-dementia populations and the all four MBI
ISTAART criteria. Notwithstanding the strengths,
there are also some limitations. Our study provides
prevalence estimates for MBI in those with MCI,
but not in those with SCC or dementia. While the
cross-sectional design has provided validation of the
MBI-C for measuring MBI in MCI patients, it is
not possible to make any conclusions in relation to
changes in prevalence over time, nor risk factors for
evolution to dementia. Longitudinal data is needed to
determine the prognostic utility of the MBI-C.
All the results together suggest that the Span-
ish version of the MBI-C is especially useful for
detecting MBI in people with MCI. There are sev-
eral implications of this finding. First, the MBI
construct is in keeping with the inclusion of behav-
ioral symptoms in the 2011 National Institute on
Aging–Alzheimer’s Association (NIA-AA) consen-
sus recommendations for diagnosis of all-cause
dementia [15]. The basis of these criteria is the
assumption that neurodegeneration may manifest
with changes in personality, behavior, or psychiatric
symptoms, prior to cognitive impairment, depending
on the type, location, and impact of the underlying
pathology. Literature has suggested, however, that
poor recruitment and retention in the early phase
illness has contributed to the lack of success in
dementia disease modifying clinical trials [41]. His-
torically, older adults with later onset NPS, who
did not show obvious cognitive impairment would
receive a psychiatric diagnosis, and the possibility
of neurodegenerative disease was often overlooked
[43, 44], resulting in inappropriate, delayed, or sub-
optimal care [45]. MBI distinguishes between formal
psychiatric illness/chronic psychiatric symptomatol-
ogy versus new onset psychiatric symptoms in older
adults, the latter of which are core to the MBI
construct of the at-risk state. The MBI-C may be
beneficial in case detection for observational and
intervention studies, selecting an enriched sample for
biomarker screening and clinical trial enrollment, dis-
entangling the confusion sometimes created by later
life NPS [13]. As it is freely available in multiple
translations (available at http://www.MBItest.org),
the MBI-C is a simple, efficient, and scalable instru-
ment that could be used in clinical settings, research
environments, or broader public health and screen-
ing initiatives. Second, while our study is focused
on the MBI-C total score, differences in prediction
of cognitive impairment based on the various aggre-
gate domain scores need to be determined. In the
ISTAART-AA MBI criteria, symptoms are divided
into the following domains: decreased motivation
[46, 47], affective dysregulation [48, 49], impulse
dyscontrol [4, 50], social inappropriateness [51, 52],
and abnormal though or perception [53, 54]. Just as
different NPS may be associated with different types
of dementias, different MBI domains may predict dif-
ferent MCI and dementia subtypes, which may have
implications for treatment [13]. The MBI research
agenda, as expressed by the ISTAART NPS pro-
fessional interest area, describes the next steps for
investigation [55]. Future studies should determine
the predictive value of MBI, with and without MCI,
for incident cognitive decline and dementia in a vari-
ety of cohorts. Additionally, biomarker correlates of
MBI are required, including imaging, known demen-
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overall goal is to better describe and capture early
manifestations of neurodegenerative disease in order
to intervene earlier. MBI-C validations are early steps
in this research agenda, but represent foundational
elements, on which to build subsequent knowledge.
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